The primary endpoint was the change from baseline in prebronchodilator FEV1 , and secondary endpoints included Asthma Control Questionnaire ( ACQ ) and Standardised Asthma Quality of Life Questionnaire [ AQLQ ( S ) ] , and incidence of exacerbations and respiratory tract infections .